The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 26, 2006
Filed:
Dec. 09, 2003
Robert J. D'amato, Lexington, MA (US);
Shawn J. Green, Vienna, VA (US);
John W. Madsen, Jefferson, MD (US);
William Fogler, Rockville, MD (US);
Glenn M. Swartz, Jr., Mt. Airy, MD (US);
Adonia E. Papathanassiu, Silver Spring, MD (US);
Jamshed H. Shah, Brookeville, MD (US);
Robert J. D'Amato, Lexington, MA (US);
Shawn J. Green, Vienna, VA (US);
John W. Madsen, Jefferson, MD (US);
William Fogler, Rockville, MD (US);
Glenn M. Swartz, Jr., Mt. Airy, MD (US);
Adonia E. Papathanassiu, Silver Spring, MD (US);
Jamshed H. Shah, Brookeville, MD (US);
The Children's Medical Center Corporation, Boston, MA (US);
Abstract
The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.